A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

Summary

A Multicenter, Nonrandomized, Open-Label Phase I/IIClinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Solid Tumors

Timeline

Start

2020-09-27

Primary completion

2028-01-25

Completion

2028-02-25

Drugs

Indications